Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection†
Article first published online: 12 JAN 2011
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 53, Issue 1, pages 317–324, January 2011
How to Cite
Charlton, M. R., Thompson, A., Veldt, B. J., Watt, K., Tillmann, H., Poterucha, J. J., Heimbach, J. K., Goldstein, D. and McHutchison, J. (2011), Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology, 53: 317–324. doi: 10.1002/hep.24074
Potential conflict of interest: One of the authors, J.M., has a significant financial interest in IL28B genotyping. To manage this potential conflict of interest, J.M. (and the entire Duke team) was blinded to all posttransplant outcomes at the time of genotyping. Only after all genotyping was performed and the results disclosed to Mayo investigators were outcomes metrics disclosed to the Duke collaborators, including J.M. No one at Mayo has any financial interest in IL28B testing. Dr. McHutchison is employed by and receives grants from Merck/Schering-Plough. Dr. McHutchison receives grants from Roche and holds intellectual property rights IL28B patent with Labcorp. Dr. Goldstein receives grants from GSK Research and holds intellectual property rights IL28B patent with Labcorp.
- Issue published online: 12 JAN 2011
- Article first published online: 12 JAN 2011
- Accepted manuscript online: 12 NOV 2010 12:48PM EST
- Manuscript Accepted: 27 OCT 2010
- Manuscript Received: 23 JUL 2010
- This work has been supported by U.S. Public Health Service grant GCRC RR00585.